Pleiotropic actions of fenofibrate on the heart

被引：34

作者：

Balakumar, Pitchai ^{[1
]}

Rohilla, Ankur ^{[2
]}

Mahadevan, Nanjaian ^{[1
]}

机构：

[1] Rajendra Inst Technol & Sci, Inst Pharm, Dept Pharmacol, Sirsa 125055, India

[2] Shri Gopi Chand Grp Inst, Dept Pharmaceut Sci, Baghpat 250609, India

来源：

PHARMACOLOGICAL RESEARCH | 2011年 / 63卷 / 01期

关键词：

Fenofibrate; PPAR-alpha; Cardiac pleiotropic action; Cardioprotection; ACTIVATED-RECEPTOR-ALPHA; VASCULAR ENDOTHELIAL DYSFUNCTION; CHRONIC PRESSURE-OVERLOAD; PPAR-ALPHA; CARDIAC-HYPERTROPHY; INDUCED HYPERTENSION; GAMMA ACTIVATORS; RATS; FIBROSIS; APOPTOSIS;

D O I：

10.1016/j.phrs.2010.11.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Fenofibrate is a third-generation fibric acid derivative employed clinically as a hypolipidemic agent to lessen the risk caused by atherosclerosis. Dyslipidemia is a condition associated with elevated levels of low-density lipoproteins (LDL), very low-density lipoproteins (VLDL) and triglycerides, and reduced levels of high-density lipoproteins (HDL) in the circulation. Fenofibrate has an ability to diminish LDL, VLDL and triglycerides and pertinently augment HDL, and thus it is used to manage dyslipidemia. The lipid lowering effects of fenofibrate are classically mediated via an activation of peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Recent studies demonstrated numerous pleiotropic effects of fenofibrate on the heart that afford direct myocardial protection besides its lipid lowering effects. Fenofibrate has an additional potential to prevent the induction and progression of hypertensive heart damage, cardiac hypertrophy, heart failure, myocarditis, lipotoxic cardiomyopathy and vascular endothelial dysfunction-associated cardiovascular abnormalities. In this review, we critically discussed recently identified pleiotropic actions of fenofibrate on the heart. Moreover, the novel cardioprotective effects of fenofibrate against various cardiac disorders have been delineated. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：8 / 12

页数：5

共 44 条

[11] Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms [J].

De Silva, Deepa S. ;

Wilson, Richard M. ;

Hutchinson, Christoph ;

Ip, Peter C. ;

Garcia, Anthony G. ;

Lancel, Steve ;

Ito, Masa ;

Pimentel, David R. ;

Sam, Flora .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2009, 296 (06) :H1983-H1993

[12] PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats [J].

Diep, QN ;

Benkirane, K ;

Amiri, F ;

Cohn, JS ;

Endemann, D ;

Schiffrin, EL .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (02) :295-304

[13] Peroxisome proliferator-activated receptor α-independent actions of Fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload [J].

Duhaney, Toni-Ann S. ;

Cui, Lei ;

Rude, Mary K. ;

Lebrasseur, Nathan K. ;

Ngoy, Soeun ;

De Silva, Deepa S. ;

Siwik, Deborah A. ;

Liao, Ronglih ;

Sam, Flora .

HYPERTENSION, 2007, 49 (05) :1084-1094

[14] Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing [J].

Farnier, Michel .

VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (05) :991-1000

[15] Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model - the Zucker diabetic rat [J].

Forcheron, Fabien ;

Basset, Alexandra ;

Abdallah, Pauline ;

Del Carmine, Peggy ;

Gadot, Nicolas ;

Beylot, Michel .

CARDIOVASCULAR DIABETOLOGY, 2009, 8

[16]

GOYA K, 2004, ARTERIOSCLER THROMB, V24, P1

[17] Fenofibrate increases creatininemia by increasing metabolic production of creatinine [J].

Hottelart, C ;

El Esper, N ;

Rose, F ;

Achard, JM ;

Fournier, A .

NEPHRON, 2002, 92 (03) :536-541

[18] Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study [J].

Huang, W. P. ;

Yin, W. H. ;

Chen, J. W. ;

Jen, H. L. ;

Young, M. S. ;

Lin, S. J. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (09) :775-783

[19] Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity [J].

Ichihara, Sahoko ;

Yamada, Yoshiji ;

Kawai, Yoshichika ;

Osawa, Toshihiko ;

Furuhashi, Koichi ;

Duan, Zhiwen ;

Ichihara, Gaku .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 359 (01) :27-33

[20] Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors [J].

Ichihara, Sahoko ;

Obata, Koji ;

Yamada, Yoshiji ;

Nagata, Kohzo ;

Noda, Akiko ;

Ichihara, Gaku ;

Yamada, Akira ;

Kato, Tomoko ;

Izawa, Hideo ;

Murohara, Toyoaki ;

Yokota, Mitsuhiro .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 41 (02) :318-329

← 1 2 3 4 5 →